Seller record · Telehealth service

KERNX Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The home, pricing and about pages and the terms say prescriptions are filled by the licensed dispensing pharmacy identified in the buyer's treatment information. 1 more criterion also fails; see the table below.

At a glance

KERNX HealthTelehealth service

6/8criteria passed

Price: Semaglutide $209 a month, tirzepatide $299, the same at every dose
Sells: compounded semaglutide, compounded tirzepatide, microdose semaglutide, and 2 more
FDA letters: None on file

Visit KERNX Health See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and tirzepatide at one monthly price for every dose, a lower-dose microdosing option and supplement packs, with care from named clinicians in an independent physician network. Care starts with an online health assessment, and no pharmacy is named.

Operating entity KERNX Health LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	KERNX Health's website; KERNX Health's about page
S2	Prescription gating	PASS	KERNX Health's website; KERNX Health's FAQ
S3	Pharmacy identification	FAIL	KERNX Health's pricing page; KERNX Health's about page; KERNX Health's terms
S4	Compounding disclosure	PASS	KERNX Health's pricing page; KERNX Health's website; KERNX Health's FAQ
S5	Analytical documentation	FAIL	KERNX Health's pricing page; KERNX Health's medications page; KERNX Health's terms
S6	Business address	PASS	KERNX Health's terms; KERNX Health's privacy page; KERNX Health's HIPAA page
S7	Price disclosure	PASS	KERNX Health's pricing page; KERNX Health's website; KERNX Health's supplements page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed independent physician reviews each patient and decides whether treatment is appropriate, and the home and about pages name the physicians and nurse practitioners who review cases.Source: KERNX Health's website; KERNX Health's about page.

S2PASSThe home page says care starts with a free health assessment and that no payment for treatment is collected before provider approval, apart from a temporary card authorization during sign up.Source: KERNX Health's website; KERNX Health's FAQ.

S3FAILNo filling pharmacy is named. The home, pricing and about pages and the terms say prescriptions are filled by the licensed dispensing pharmacy identified in the buyer's treatment information.Source: KERNX Health's pricing page; KERNX Health's about page; KERNX Health's terms.

S4PASSThe pricing page, the answers and the home page describe the medications as compounded and state that compounded medications are not FDA-approved and are not the same as the approved brand products.Source: KERNX Health's pricing page; KERNX Health's website; KERNX Health's FAQ.

S5FAILNo certificate of analysis or lot document is published on the pricing page, the medications page, the answers or the terms.Source: KERNX Health's pricing page; KERNX Health's medications page; KERNX Health's terms.

S6PASSKERNX Health LLC at PO Box 2496, 3320 Post Office Rd, Woodbridge, VA 22195, a post office box printed in the footer of the terms, the privacy policy and the HIPAA notice; other pages give only Washington, DC. The terms name District of Columbia law.Source: KERNX Health's terms; KERNX Health's privacy page; KERNX Health's HIPAA page.

S7PASSCompounded semaglutide at $209 a month and compounded tirzepatide at $299 a month, the same at every published dose, with no membership fee and no required multi-month plan. The lower-dose microdosing option lists semaglutide at $179 for 1 month or $507 for 3 months and tirzepatide at $199. Supplement packs from $109 a month.Source: KERNX Health's pricing page; KERNX Health's website; KERNX Health's supplements page.

S8PASSNo FDA warning letter names KERNX Health or KERNX Health LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, microdose semaglutide, microdose tirzepatide, supplement packs.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit KERNX Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.